Scarica l'app Stockscreener
52.97
0.85%
0.445
Pre-mercato:
52.96
-0.005
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$52.52
Aprire:
$52.57
Volume 24 ore:
555.50K
Relative Volume:
0.42
Capitalizzazione di mercato:
$5.43B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-14.20
EPS:
-3.73
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
-4.89%
1M Prestazione:
+10.44%
6M Prestazione:
+70.91%
1 anno Prestazione:
+38.62%
Intervallo 1D:
$51.77
$53.27
Intervallo di 1 settimana:
$51.77
$56.99
Portata 52W:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Confronta CRNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
52.97 | 5.38B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Momentum Shift: Can Crinetics Pharmaceuticals Inc. stock outperform in a bear marketWeekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities - Investing.com
Why (CRNX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: Is Crinetics Pharmaceuticals Inc exposed to currency risks2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Jim Cramer on Crinetics: "That's a Better Spec Than Aquestive" - Finviz
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - Sahm
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Analyst Calls: How risky is Crinetics Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - Улправда
Citizens Jmp Has Lowered Expectations for Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price - MarketBeat
Crinetics Pharmaceuticals (CRNX): Analyst Updates on Price Targe - GuruFocus
Crinetics stock price target lowered to $105 by Citizens on endocrinologist survey - Investing.com UK
US Market Wrap: Will Crinetics Pharmaceuticals Inc 6Z4 stock issue positive guidance2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics’ Stocks Surge: Promising Future or Mirage? - timothysykes.com
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crinetics Pharmaceuticals Inc Azioni (CRNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kalofonos Isabel | Chief Commercial Officer |
Jan 05 '26 |
Sale |
55.00 |
2,500 |
137,500 |
834 |
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):